Shionogi & Co. says it will acquire Atlanta-based Sciele Pharma Inc. in an all-cash deal valued at $1.42 billion, buying sales channels and access to a better clinical-study environment in the U.S. market.
The midsize, Osaka-based pharmaceutical company said it will offer $31 for each Sciele share in a tender offer starting in 10 business days and lasting 20 days.
